ThalesNano and Sanofi to examine process chemistry

By Gareth Macdonald

- Last updated on GMT

Related tags: Sanofi, Pharmacology

Process chemistry specialist ThalesNano and Sanofi-aventis R&D
are teaming up to examine the development and implementation of
continuous process technologies in the latter's manufacturing
facilities.

The collaboration, financial terms of which have not been disclosed, will specifically focus on applying ThalesNano's integrated chemistry technologies to Sanofi's drug discovery and active pharmaceutical ingredient (API) development operations, both at the research and commercial level. Like all major companies operating in the increasingly competative global pharmaceutical sector, Sanofi-aventis is actively looking to cut costs in all aspects of its business, including in its drug discovery programme. In an article in the UK's Daily Telegraph​ earlier this month, Nigel Brooksby managing director of Sanofi-Aventis UK commented that bringing a blockbuster "medicine to market takes 10-12 years at a cost of around $1bn. The risk of failure is high: 79 per cent of investigational new drugs fail in clinical development. The changing landscape is increasing the pressure on the current blockbuster business model and the traditional development process​." Sanofi first to test ThalesNano's kit ​ ThalesNano's chief executive, Laszlo Urge, told in-PharmaTechnologist that the project will begin testing the Hungarian firm's technology at Sanofi's Paris facility but added that the collaboration may be extended to include other Sanofi manufacturing sites. Dr Urge commented that "Sanofi will be among the first [companies to] have immediate access to all the new developments and technologies and could be the first to implement them in their R&D and production [operations]."​ The overall aim of the collaboration is to develop "a harmonized continuous process technology from discovery to full scale production. As a result the entire company can gain on the efficiency of the technology​," Urge explained. He added that "in general in many of the pharmaceutical companies, technologies applied in discovery, development and production can differ a lot. As a result, quite often it is time consuming to move compounds and project to scale up, and the time lost due to this is tremendous. If you translate it into dollars, every month delay in the development of a blockbuster project means minimum $100m revenue delay for a major pharmaceutical company​." Urge added that moves to expedite production can also have a positive societal impact "since new drugs can be put on the market faster. In addition current drugs may be produced cheaper and more effectively."​ Echoing these thoughts, Dr Christophe Daubie, head of Chemical Development for the Paris area at Sanofi R&D added that: "This collaboration is important also because it enters into the scope of Sanofi-aventis R&D strategy in terms of our constant involvement in safety considerations, quality improvement of our processes with respect to environmental and industrial hygiene aspects, including green chemistry​."

Related news

Show more

Related products

show more

Strategies to Achieve Successful Approval & Launch

Strategies to Achieve Successful Approval & Launch

Catalent Pharma Solutions | 03-Sep-2020 | Data Sheet

There are several key considerations to how companies should approach commercial-scale manufacturing that may aid the success of their biologic’s launch...

Follow us

Products

View more

Webinars